tbuckley/cabot-search huggingface dataset:
139P Multimodal prognosis modeling of advanced NSCLC treated with first-line immunochemotherapy: Integrating genomic and microenvironmental data
Authors: Y. Hu, Y. Han, D. Huang, X. Liu, J. Ma, J. Wang, Z. Liu, L. Wang, F. Zhang, B. Yang, H. Tao, W. Xiao, H. Wang, J. Wen, H. Gao, H. Qin, X. Li, S. Liu, J. Hu
Journal: Annals of Oncology (2024)
147P Comparison of immune-checkpoint inhibitor therapy predictive marker tests microsatellite instability (MSI) and mismatch-repair deficiency (dMMR)
Authors: M.L. Nádorvári, J. Timar, J. Kulka, I. Kenessey, T. Barbai, A. Kiss, E. Rásó
Journal: Annals of Oncology (2024)
64O Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay for MRD in head and neck cancers
Authors: G. Liu, S.H. Huang, L. Ailles, K. Rey-McIntyre, B. Brown, J.T. Jones, Y. Wang, C. Melton, J. Bergener, J. Zhang, O. Hall, J. Min, S.Y. Shen, J. Provance, E. Sosa, B. Allen, A. Licon, J. Zhang, A-R. Hartman, D. De Carvalho
Journal: Annals of Oncology (2024)
135P Soluble PD-L1 (sPD-L1) as a predictive biomarker in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) in the first-line setting
Authors: A.E. Costantini, P. Takam Kamga, C. Capron, J-F. Emile, E. Giroux-Leprieur
Journal: Annals of Oncology (2024)
17P Breaking chemotherapy resistance in gastric adenocarcinoma: Immunogenic cell death induction by carbonic anhydrase IX targeting
Authors: E. Andreucci, A. Biagioni, S. Peri, G. Versienti, F. Cianchi, C. Supuran, L. Calorini, L. Magnelli, L. Papucci
Journal: Annals of Oncology (2024)
278P Prognostic and biologic significance of HER2-low early-stage breast cancer with long-term follow-up
Authors: Y. Niwa, Y. Wanifuchi-Endo, T. Fujita, T. Asano, K. Nozawa, N. Matsumoto, A. Isogai, Y. Tanaka, T. Toyama
Journal: Annals of Oncology (2024)
290P Subtype-specific prognostic value of lobular histology in patients with early-stage breast cancer: A nationwide population-based study
Authors: G. Nader Marta, L. Ameye, D. Martins Branco, R.F. Salgado, N. Van Damme, J. Verbeeck, P.G. Aftimos, L. Buisseret, M. Paesmans, C. Molinelli, M. Lambertini, K. Van Baelen, C. Desmedt, M. Piccart, E. de Azambuja
Journal: Annals of Oncology (2024)
45P Durvalumab (D) plus gemcitabine-based (gem-based) chemotherapy as first-line therapy for Chinese patients (pts) with advanced biliary tract cancers (aBTC): A phase IIIb, single arm, open-label, multi-center study (TopDouble)
Authors: H. Sun, J. Zhou, S. Qin, T. Zheng, Z. Geng, Y. Yuan, J. Zhou, J. Liu, H. Li, S. Gu, T. Li, B. Zhang, J. Yue, H. Zhao, L-X. Liu, Z. Huang, Z. Zhang, J. LI, J. Zhang, Z. Su
Journal: Annals of Oncology (2024)
4P CBL-B inhibition overcomes PD-1/LAG-3 mediated resistance in lung cancer
Authors: L.D.E. Chocarro, E. Blanco, L. Fenández-Rubio, M. Garnica, M. Zuazo, M.J. Garcia Granda, A. Bocanegra, M. Echaide, C. Johnston, C.J. Edwards, J. Legg, A. Pierce, H. Arasanz, G. Fernandez-Hinojal, R. Vera, K. Ausin, E. Santamaría, J. Fernández-Irigoyen, G. Kochan, D. Escors
Journal: Annals of Oncology (2024)
141P Circulating immune cells predict immunotherapy benefit in patients with triple negative breast cancer: Preliminary results from the IRIS study
Authors: B. Conte, V. Martini, R. Alsati, R. Boldorini, S. Gobbato, L. Negrini, R. Ben Ayed, B. Ruffilli, F. Vezzoli, N. Sala, L. Matera, C. Branni, V. Rossi, I. Taglialatela, F. D'Avanzo, A. Gennari
Journal: Annals of Oncology (2024)
10P Multivariate analysis of functional organoid assays predicts patient responses in the clinic for colorectal and pancreatic cancer
Authors: A-R. Gryspeert, J. Cartry, A. Boileve, J.R. Mathieu, G. Altay, M.P. Ducreux, D-L. Pagès, F. Jaulin, G. Ronteix
Journal: Annals of Oncology (2024)
122P Practice patterns and treatment outcomes of molecular tumour board (MTB)-based personalized cancer therapies: A single-center experience
Authors: F. Moik, J.M. Riedl, L. Edlinger, T. Esterl, S. Hasenleithner, S. Kostmann, L. Cebular, S. Jahn, K. Kashofer, M. Zacharias, G. Hoefler, E. Heitzer, A. Gerger, P.J. Jost
Journal: Annals of Oncology (2024)
23P Germline testing in a selected cohort of non-small cell lung cancer (NSCLC) patients: Final results from the INHERITY LC study
Authors: M. Zurera Berjaga, L. Mezquita, O. Higuera Gomez, J.C. Laguna Montes, S. Menao-Guillen, M. Arruebo, C. Lahuerta, J. de Castro Carpeño, M.D. Isla Casado, R. Lastra
Journal: Annals of Oncology (2024)
109P Development and validation of a digital PCR assay for detection and monitoring of universally methylated circulating tumor DNA in patients with high-grade sarcoma
Authors: E. Ashton, V. Taly, C. Tlemsani, A. Gaudet-Chardonnet, B. Parfait, J. Abdelli, F. Larousserie, V. Audard, V. Dumaine, D. Biau, P. Anract, S. Larrede, L. Waechter, J. Noel, S. De Percin, P. Boudou Rouquette, F. Goldwasser, P. Laurent-Puig, J. Alexandre, G. Beinse
Journal: Annals of Oncology (2024)
265P Association of clinical benefit of adjuvant capecitabine and RCB class in triple negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy
Authors: S. Lee, J. Hyung, H. Jeong, J-H. Ahn, K.H. Jung, S-B. Kim, H.J. Lee, G. Gong, H.J. Kim, J.W. Lee, B-H. Son, S.B. Lee, J. Jeong
Journal: Annals of Oncology (2024)
93P UriMee: A novel non-invasive test for diagnosis of urothelial carcinoma by detection of methylation markers in urinary sediment DNA
Authors: M. Cao, G. Yang, L. Zhang, D. Wang, T. Zhao, Y. Cao, H. Chen, D. Jin, R. Zhang, W. Liu, Y. Zhang, Y. Hao, N. Xue, W. Xue
Journal: Annals of Oncology (2024)
1O The somatic mutation landscape of the normal and malignant pancreas
Authors: P.A. Nicola, A.R.J. Lawson, P. Scott, F. Abascal, A. Cagan, L.M.R. Harvey, Y. Hooks, H. Savin, K.T.A. Mahbubani, B. Basu, M. Stratton, A. Paterson, K. Saeb-Parsy, I. Martincorena
Journal: Annals of Oncology (2024)
262P Predictive clinico-biological factors of toxicity associated to neo-adjuvant chemo- immunotherapy in early-stage triple-negative breast cancer
Authors: E. Volant, J-S. Frenel, L. Campio, J. Quintin, A. Patsouris, P. Augereau, M-F. Heymann, R. Movassaghi, M. CAP, M. Campone, M. Robert
Journal: Annals of Oncology (2024)
43P A redesigned cell atlas of colon cancers to better assess their cellular composition
Authors: M. Sroussi, C.D.S. Groeneveld, L. Jerman, G. Cabrejas, C. Gallois, T. Balde, H. Guichard, S. Doublier, J. Raciazek, O. Bouche, T. Aparicio, C. Pilati, S. Mouillet-Richard, J-F. Emile, J. Taieb, A. Griffiths, P. Laurent-Puig, A. de Reynies
Journal: Annals of Oncology (2024)
130P Ipilimumab plus nivolumab (Ipi+Nivo) in patients with tumors harboring high tumor mutational burden or load (TMB/TML-H): Results from the Drug Rediscovery Protocol (DRUP)
Authors: S.F. Haj Mohammad, K. Verkerk, L.J. Zeverijn, B.S. Geurts, I.A.C. Spiekman, F. Verbeek, P. Roepman, A. Jansen, W. de Leng, D. Robbrecht, S. Marchetti, H.M.W. Verheul, E.E. Voest, H. Gelderblom
Journal: Annals of Oncology (2024)
345MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study
Authors: C. Lemech, Y. Sun, A. Nagrial, X. Wu, M. Morris, F. Ning, J. Yang, Y. Pan, J. Cai, P. Lu, T. Zhang, F. Qiu, C. Hu, M. Zhang, Z. Liu, G. Han, J. Nie, C. Teng, H. Zhou, D. Day
Journal: Annals of Oncology (2024)
56P Multi-omic profiling in cholangiocarcinoma to enable scientific advancement within the DKFZ/NCT/DKTK MASTER study
Authors: F. Nichetti, F. Korell, M. Schwab, P.K.M. Hoffmeister, J. Hüllein, S. Uhrig, M-V. Teleanu, S. Kreutzfeldt, P. Horak, H. Glimm, C. Heining, D.T. Rieke, T. Kindler, D. Hübschmann, C. Springfeld, M. Jenzer, C.E. Heilig, S. Fröhling, B.C. Köhler
Journal: Annals of Oncology (2024)
60P Baseline characteristics and molecular testing of patients with IDH1-mutated cholangiocarcinoma: Initial results from the phase IIIb ProvIDHe study
Authors: L. Rimassa, J.A. Bridgewater, A. Casadei Gardini, H. Wilmink, H-W. Sim, J. de Vos-Geelen, T. Macarulla Mercade, D. Malka, H. Gharbi, R. Robert, A. Sullivan, A. Vogel
Journal: Annals of Oncology (2024)
235MO Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE
Authors: S. Loi, E. Stringer-reasor, J-S. Frenel, M. Reinisch, R. ORegan, M. De Laurentiis, Y.H. Park, A. O'Dea, Y-S. Lu, V. Gonzalez, M. Gao, S. Waters, H. Hu, B. Xu
Journal: Annals of Oncology (2024)
41P Cancer therapy-related cardiac dysfunction (CTRCD) after radiation therapy for breast cancer: Results of the French BACCARAT study
Authors: M.K.F. Honaryar, M. Locquet, R. Allodji, G. Jimenez, O. Lairez, L. Panh, J. Camilleri, D. Broggio, J. Ferrières, F. De Vathaire, S. Jacob
Journal: Annals of Oncology (2024)
90P Clonal haematopoiesis of indeterminate potential (CHIP) might mislead interpretation of ATM and CHEK2 alterations detected on liquid biopsies
Authors: P. Rescigno, A. Mahmood, M. Lagonera, S. Bashir, N. Haris, A. Mohammed, A. Shaheen, A. Gautam, E. Taylor, J. Smith, S. Rae, C. MacCormack, L. Hogarth, C. Oing, R. Plummer, A. Greystoke
Journal: Annals of Oncology (2024)
69MO Organ-specific performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort
Authors: C. Douville, V. Gainullin, K. Arvai, M. Gray, M. Kumar, M. Manesse, X. Chen, P. Uren, G. Cerqueira, G. Silvestri, D. Chesla, R. Given, A. Mazloom, J. Garces, T.M. Beer, F. Diehl
Journal: Annals of Oncology (2024)
86P Making the precision oncology landscape of Europe and the Republic of Ireland programmatically accessible
Authors: B. Reardon, C. Flannery, J. Karam, M. Lynch, K. Meli, T. Pappa, J. Park, E. Saad, M. Shady, M. Vergara, E.M. Van Allen, A. Culhane
Journal: Annals of Oncology (2024)
11P Therapeutic effects of MRTX1133 in KRAS G12D mutant appendiceal cancer: Insights from organoid and in vivo studies
Authors: J.P.Y-C. Shen, S. Chowdhury, I. Ito, V.K. Pattalachinti, A.M. Yousef, M.M.G. Yousef, M.M. Fanaeian
Journal: Annals of Oncology (2024)
244P Efficacy and safety of dalpiciclib, exemestane, and goserelin as neoadjuvant therapy in premenopausal HR-positive, HER2-negative breast cancer patients: A phase II clinical trial
Authors: Y. Zhengjun, A. Chen, M. Ran, Z. Ying, L. Hong, J. Ge, H. Ruixue, B. Jianping, C. Xuchen, X. Wang
Journal: Annals of Oncology (2024)
54P BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic biliary tract carcinoma (BTC)
Authors: Z. Lu, L. Chang, J. Zhou, Y. Ji, M. Sun, Q. Wen, S.G. Gao, X.L. Ma, D. Zhong, Q. Guo, S. Xiao, H. Wang, H. Zhu, Y. Zhu, L. Shen
Journal: Annals of Oncology (2024)
68O Frequency of clinical acquired RAS-MAPK pathway resistance alterations in patients treated with KRASG12C inhibitors: An individual patient meta-analysis
Authors: J.M. Riedl, F. Fece, B. Caughey, H. Matsubara, P. Patel, A. Varkaris, H. Barnes, S. Ehnstrom, J. Schwartz, J.J. Lin, A. Parikh, J. Gainor, A. Hata, R. Heist, R.B. Corcoran
Journal: Annals of Oncology (2024)
84P Advancing precision oncology: Integrating immune landscape and genomics for tailored therapy in metastatic cancer patients
Authors: E. Angeli, V. Debien, A. Besson, M. Brunet, A. Moreau, A. Bourdon, P. Dubos, F. Peyraud, L. Vanhersecke, M. Alamé, L. Blouin, E. Khalifa, I. Soubeyran, S. Cousin, A. Italiano
Journal: Annals of Oncology (2024)
74MO Impact of MTAP loss on prognosis and efficacy of immune check point inhibitors across advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-1
Authors: K. Seguchi, T. Fujisawa, S. Ikeda, Y. Oyama, S. Kadowaki, C. Morizane, M. Ueno, E. Oki, W. Yamagami, S. Yuki, N. Nonomura, H. Iwata, H. Watari, S. Okano, K. Namikawa, H. Bando, T. Yoshino, Y. Nakamura
Journal: Annals of Oncology (2024)
103P Epigenetic regulated genes enhanced fragmentomics-based model for early-stage lung cancer detection
Authors: Y. Wang, H. Li, Z. Feng, L. Song, H. Wang, Z. Huang, B. Li, T. Gu, S. Hong, F. Zhao, H. Jin, S. Tong, B. Zhou, C. Guo, S. Zhu, C. Zhu, J. Song, X. Sun, S. Li, N. Liang
Journal: Annals of Oncology (2024)
104P The development of a classifier of somatic copy number alteration burden in liquid biopsy with potential clinical impact in advanced non-small cell lung cancer (NSCLC)
Authors: L. Bonanno, V. Tosello, L.C. Bao, A. Grassi, D. Rose, E. Zulato, C. Delle Fratte, M. Polano, G. Pasello, V. Guarneri, S. Indraccolo
Journal: Annals of Oncology (2024)
160P Predicting immune-related adverse events using biomarkers in early-phase cancer immunotherapy trials
Authors: B.P. Fairfax, V.C. Schmid, D.F. Lamparter, T. Kam-Thong, P. Scepanovic, G. Duchateau-Nguyen, A. Roller, R. Mohindra, V. Karanikas, D. Heinzmann, C. Adams, S.L. Mycroft, N. Städler
Journal: Annals of Oncology (2024)
50P Camrelizumab (Cam) combined with gemcitabine and cisplatin (GP) plus low-dose apatinib in first-line treatment of advanced biliary tract cancer (BTC)
Authors: Y. Lu, D. Zhang, Y. Zhang, F. Liu, Z. Wang, F. Wang, Y. Li, F. Wang, H.Y. Luo, G. Guo, M. Qiu, D. Wang, D. Chen, Y. Jin, Y. Liu, J. Chen, R-H. Xu
Journal: Annals of Oncology (2024)
115P Gene rearrangements, actionability and access to precision medicine: Results from the ARCAGEN study
Authors: M. Morfouace, J. Oliveira, J. Peron, M. Pracht, N. Penel, S. Tejpar, M-S. Robert, H.J. Klumpen, R. Peeters, L.F.L. Licitra, N. Girard, J.A. Gietema, W.W. de Herder, E. Kapiteijn, A. Idbaih, I.L. Ray-Coquard, J-Y. Blay
Journal: Annals of Oncology (2024)
82P Clinical and molecular characteristics of gynecologic cancer patients in FINPROVE: The national phase II drug repurposing trial in Finland
Authors: A. Färkkilä, A. Suoknuuti, H.J. Lassus, M.M.E. Tanner, E. Alanne, O-S. Kääriäinen, S.M.E. Iivanainen, A. Auranen, M.K. Simojoki, J. Arola, A. Pasanen, E. Niemela, R. Vainionpää, E. Kaikkonen, A. Virtanen, S. Kytölä, K. Jalkanen
Journal: Annals of Oncology (2024)
133P Neoadjuvant pembrolizumab plus lenvatinib in resectable stage III melanoma patients (pts) (NeoPele): Analysis of the peripheral immune profile correlated to pathological response
Authors: I. Pires da Silva, J.W. Conway, L.A. Smith, A. Ramanathan, N.A. Adegoke, R. Rawson, P. Grover, N. Maher, J. Braden, M. Gonzalez, U. Palendira, A.M. Menzies, R.A. Scolyer, G.V. Long
Journal: Annals of Oncology (2024)
59P Prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: Results from the French prospective FFCD cohort
Authors: G. Roth, A. Pellat, G. Piessen, K. Le Malicot, L. Schwarz, C. Gallois, D. Tougeron, V. Hautefeuille, M. Jary, S. Benoist, J-F. Ramee, R. Desgrippes, M. Muller, S. Manfredi, O. Bouche, J. Taieb
Journal: Annals of Oncology (2024)
67O Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity
Authors: C.W. Thorball, Z. Quandt, A. Saha, L. Yao, P. Midda, Y. Xu, C.A. Bejan, F. Hodel, A. Stravodimou, E. Shearer-Kang, M. Aldrich, E.J. Philips, G. Liu, A. Schoenfeld, D. Johnson, E. Ziv, J. Fellay, R. Mohindra, J.M. Balko, G.S. Chandler
Journal: Annals of Oncology (2024)
105P Plasma ctDNA dynamics as clinical response biomarker for NSCLC: A systematic review and meta-analysis
Authors: L.F. Leite, E.F. Saldanha, L. Halamy, J.S.A. de Menezes, I.R. Buonopane, J.A. Bragança dos Santos, C.U. de Menezes, G. Lopes
Journal: Annals of Oncology (2024)
51P A phase II trial of camrelizumab in combination with hepatic arterial infusion chemotherapy (HAIC) for initially unresectable advanced extrahepatic cholangiocarcinoma (eCCA) and gallbladder cancer (GBC): An interim report
Authors: L. Yu, K. Chen, J. Ye, W. Liu, W. Zhai
Journal: Annals of Oncology (2024)
57P Integrative analysis of the genomic and transcriptomic landscape identifies ciliary genes as a therapeutic target in bile duct cancer
Authors: P. Carotenuto, F. Piscopo, A. Barbato, C. Pollastro, L. Ferrante, L. Evangelista, G. Gitano, A. Iuliano, P. Pisapia, M. Salatiello, A. Iaccarino, U. Malapelle, G. Troncone, G. Grisendi, L. Reggiani-Bonetti, M. Salati, M. Dominici, B. Franco
Journal: Annals of Oncology (2024)
26P Multi-feature cell free DNA analysis and ensemble machine learning for early detection of cancer
Authors: S. Jeong, Y. Jeon, Y-J. Kim, D. Go, H.G. Woo, Y.T. Kim, K.H. Kim, H-B. Lee, Y.W. Kim, J.K. Park, Y. Lim, S.Y. Kim, S-H. Song, H-P. Kim, D. Bang, T-Y. Kim
Journal: Annals of Oncology (2024)
63O Transcriptional features of stage IIT4N0/III colon cancer associated with residual disease and ctDNA status after surgery in the PEGASUS trial
Authors: E. Medico, F.M. Buffa, C. Isella, G. Skenderi, L. Lazzari, M. Prisciandaro, S. Lonardi, N. Tarazona Llavero, C. Montagut Viladot, A. Sartore Bianchi, M.G. Zampino, M.E. Elez Fernandez, C. Santos Vivas, M. Mandalà, S. Tamberi, A. Calon, A. Cervantes, S. Siena, A. Bardelli, S. Marsoni
Journal: Annals of Oncology (2024)
89P Comprehensive genomic profiling of circulating tumor DNA for treatment recommendation: A sub-project of the IMPRESS-Norway trial
Authors: I. Dyvik, L. Fagereng, T. Lien, V. Nygaard, L. Silwal-Pandit, J.C. Noone, A.B. Wennerström, A.J. Skjulsvik, K.M. Ersland, T.K.K. Guren, K. Puco, S. Brabrand, E.S. Blix, A. Flobak, A. Haug, K.A.M. Johansson, S. Smeland, K. Tasken, A. Helland, H.E.G. Russnes
Journal: Annals of Oncology (2024)
44P Chemo-immunotherapy combination of mFOLFOX6, bevacizumab and atezolizumab after first-line therapy for advanced biliary tract cancer: The COMBATBIL imCORE trial
Authors: M. Ponz-Sarvise, T. Gromke, A. Landa Magdalena, H. Richly, S-T. Liffers, S. Kasper-Virchow, R. Garonce-Hediger, E. Castanon Alvarez, L. Ceniceros Paredes, A. Chopitea Ortega, J.T. Siveke
Journal: Annals of Oncology (2024)
246P Axillary management and outcomes after neoadjuvant endocrine therapy in the randomized PELOPS trial
Authors: A.C. Weiss, Q. Jin, N. Tayob, E. Wrabel, M. DeMeo, J. Carter, M.A.A. Fenton, M. Constantine, C. Block, M. Faggen, K.M.S. Lo, T. Openshaw, D. Yardley, L.C. Kennedy, I. Bedrosian, E. Mittendorf, O. Metzger, T.A. King, H. Hachem
Journal: Annals of Oncology (2024)
136P Circulating hPG80 (WNT pathway activation) as a potential new prognostic/predictive factor of immunotherapy (ICI) efficacy: ONCOPRO prospective study
Authors: B. You, P. Ceruse, S. Couraud, M. Duruisseaux, P. Paparel, L. Badet, O. Pelton, F. Subtil, A. Gelot, J. Dubreuil, E. Aubret, V. Pitiot, M. Piecyk, G. Lescuyer, B. Vire, S. Calattini, A. Carrot, L.F-G. Payen
Journal: Annals of Oncology (2024)
101P Circulating tumor DNA minimal residual disease predicts the risk of progression after long-term response to first-line immunotherapy in advanced NSCLC
Authors: F. Wu, Y. Peng, Y. Zeng, Z. Qiu, F. Ma, L. Zhu, C. Zhou, X. Pu, L. Zhang, Y. Zhou, J. Weng, S. Zengmei, J. Yu, Z. Zhou, R. Meng, Q. Bu, P. Liu, J. Li, S. Chen, L. Cui
Journal: Annals of Oncology (2024)
2P Single-cell profiling and integrative TCR analysis reveals tumor-mutation associated phenotypes and immune repertoire in lung adenocarcinoma
Authors: A.X. Lozano, M. Ghaedi, A. Azarmina, A. Sayad, S.C. Lien, S. Soleimani, D.C. Chung, N. Jacquelot, T.K. Waddell, K. Yasufuku, M. de Perrot, L. Eng, F.A. Shepherd, P.A. Bradbury, N.B. Leighl, G. Liu, M-S. Tsao, T.J. Pugh, P.S. Ohashi, A.G. Sacher
Journal: Annals of Oncology (2024)
6P Circulating low-density neutrophils (LDNs) are associated with resistance to immunotherapy as frontline treatment for non-small cell lung cancer (NSCLC): Updated results and proteomic characterization
Authors: N. Castro Unanua, O. Fontecha, L. Teijeira Sanchez, M. Martínez-Aguillo, I. Morilla Ruiz, I. Labiano, A.E. Huerta-Hernández, A. Lecumberri, I. Caseda, M. Alsina Maqueda, R. Vera, H. Arasanz
Journal: Annals of Oncology (2024)
Urinary Extracellular Vesicles Carrying Klotho Improve the Recovery of Renal Function in an Acute Tubular Injury Model
Authors: Cristina Grange, Elli Papadimitriou, Veronica Dimuccio, Cecilia Pastorino, Jordi Molina, Ryan O’Kelly, Laura J. Niedernhofer, Paul D. Robbins, Giovanni Camussi, Benedetta Bussolati
Journal: Molecular Therapy (2024)
Reply to Rongkang Li, Lei Peng, Shaohua Zhang, and Song Wu’s Letter to the Editor re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death—Results from the Norwegian Prostate Cancer Consortium. Eur Urol 2024;86:20–6
Authors: Johan Bjerner, Ola Bratt, Kirsti Aas, Peter C Albertsen, Sigrid V Carlsson, Jan Oldenburg
Journal: European Urology (2024)
Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer
Authors: Adam B Weiner, Raag Agrawal, Nicholas K Wang, Ida Sonni, Eric V Li, Jaron Arbet, J J H Zhang, James A Proudfoot, Boon Hao Hong, Elai Davicioni, Nathanael Kane, Luca F Valle, Amar U Kishan, Alan Dal Pra, Pirus Ghadjar, Christopher J Sweeney, Nicholas G Nickols, R Jeffrey Karnes, John Shen, Matthew B Rettig, Johannes Czernin, Ashely E Ross, Melvin Lee Kiang Chua, Edward M Schaeffer, Jeremie Calais, Paul C Boutros, Robert E Reiter
Journal: European Urology (2024)
Environmentally sustainable prescribing: recommendations for EU pharmaceutical legislation
Authors: Joost D Piët, Amy Booth, Erik M Donker, Fabrizio de Ponti, Carlotta Lunghi, Elisabetta Poluzzi, Ben J A Janssen, SanYuMay Tun, Charlotte Bekker, Lorena Dima, João Costa, Mathilde Jalving, Thijs H Oude Munnink, Patricia M L A van den Bemt, Marc Labriffe, Tomás van Emden, Vera van Waardenburg, Robert Likic, Milan Richir, Michiel A van Agtmael, Caroline T A Moermond, Jelle Tichelaar
Journal: The Lancet Planetary Health (2024)
Computer-aided diagnosis for the resect-and-discard strategy for colorectal polyps: a systematic review and meta-analysis
Authors: Cesare Hassan, Tommy Rizkala, Yuichi Mori, Marco Spadaccini, Masashi Misawa, Giulio Antonelli, Emanuele Rondonotti, Evelien Dekker, Britt B S L Houwen, Oliver Pech, Sebastian Baumer, James Weiquan Li, Daniel von Renteln, Claire Haumesser, Roberta Maselli, Antonio Facciorusso, Loredana Correale, Maddalena Menini, Alessandro Schilirò, Kareem Khalaf, Harsh Patel, Dhruvil K Radadiya, Pradeep Bhandari, Shin-Ei Kudo, Shahnaz Sultan, Per Olav Vandvik, Prateek Sharma, Douglas K Rex, Farid Foroutan, Alessandro Repici
Journal: The Lancet. Gastroenterology & hepatology (2024)
Dietary vitamin B3 supplementation induces the antitumor immunity against liver cancer via biased GPR109A signaling in myeloid cell
Authors: Yang Yang, Tianduo Pei, Xiaolin Hu, Yu Lu, Yanqiu Huang, Tingya Wan, Chaobao Liu, Fengqian Chen, Bao Guo, Yuemei Hong, Qian Ba, Xiaoguang Li, Hui Wang
Journal: Cell Reports Medicine (2024)
Targeting NAT10 inhibits osteosarcoma progression via ATF4/ASNS-mediated asparagine biosynthesis
Authors: Yutong Zou, Siyao Guo, Lili Wen, Dongming Lv, Jian Tu, Yan Liao, Weidong Chen, Ziyun Chen, Hongbo Li, Junkai Chen, Jingnan Shen, Xianbiao Xie
Journal: Cell Reports Medicine (2024)
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial
Authors: Nicholas J Short, Daniel Nguyen, Elias Jabbour, Jayastu Senapati, Zhihong Zeng, Ghayas C Issa, Hussein Abbas, Cedric Nasnas, Wei Qiao, Xuelin Huang, Gautam Borthakur, Kelly Chien, Fadi G Haddad, Naveen Pemmaraju, Omer S Karrar, Danielle Nguyen, Marina Konopleva, Hagop Kantarjian, Farhad Ravandi
Journal: The Lancet Haematology (2024)
Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction
Authors: Hyukjin Park, Nuri Lee, Cho Hee Hwang, Sang-Geon Cho, Ga Hui Choi, Jae Yeong Cho, Hyun Ju Yoon, Kye Hun Kim, Youngkeun Ahn
Journal: JACC CardioOncology (2024)
Development of rheumatoid arthritis after methotrexate in anticitrullinated protein antibody-negative people with clinically suspect arthralgia at risk of rheumatoid arthritis: 4-year data from the TREAT EARLIER trial
Authors: Quirine A Dumoulin, Doortje I Krijbolder, Karen Visser, Leroy R Lard, Annette H M van der Helm-van Mil
Journal: The Lancet Rheumatology (2024)